Positions

Overview

  • James A. Bonner, M.D., is Senior Advisor to the Director of the UAB Comprehensive Cancer Center and the Merle M. Salter Endowed Chair in Radiation Oncology. A member of the UAB faculty since 1998, Dr. Bonner served as co-leader of the Cancer Center’s Experimental Therapeutics Program from 1998 to 2010.

    Dr. Bonner received his undergraduate degree from Duke University and his M.D. from Wayne State University. His research interest focuses on methods of enhancing radiosensitization such as combinations of chemotherapy or targeted therapy with radiotherapy. His current laboratory interests are directed at the development of single chain antibodies that target the epidermal growth factor receptor and can be delivered in a gene therapy approach.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Myristoylated alanine-rich C-kinase substrate effector domain phosphorylation regulates the growth and radiation sensitization of glioblastomaInternational Journal of Oncology.  54:2039-2053. 2019
    2019 A competing risk nomogram to predict severe late toxicity after modern re-irradiation for squamous carcinoma of the head and neckOral Oncology.  90:80-86. 2019
    2019 Gender, Professional Experiences, and Personal Characteristics of Academic Radiation Oncology Chairs: Data to Inform the Pipeline for the 21st CenturyInternational Journal of Radiation Oncology - Biology - Physics2019
    2019 Treatment intensity in locoregionally advanced head and neck cancer: Recent investigation leads to new questionsTranslational cancer research.  8:S188-S194. 2019
    2018 In Regard to Bossi et alInternational Journal of Radiation Oncology - Biology - Physics.  102:669-670. 2018
    2018 Qualitative Assessment of Academic Radiation Oncology Department Chairs' Insights on Diversity, Equity, and Inclusion: Progress, Challenges, and Future AspirationsInternational Journal of Radiation Oncology - Biology - Physics.  101:30-45. 2018
    2018 A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck CancerInternational Journal of Radiation Oncology - Biology - Physics.  100:595-605. 2018
    2018 Refining Patient Selection for Reirradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-institution Cohort Study by the MIRI CollaborativeInternational Journal of Radiation Oncology - Biology - Physics.  100:586-594. 2018
    2018 Volume, Dose, and Fractionation Considerations for IMRT-based Reirradiation in Head and Neck Cancer: A Multi-institution AnalysisInternational Journal of Radiation Oncology - Biology - Physics.  100:606-617. 2018
    2018 ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damageJournal of Biological Chemistry.  293:984-994. 2018
    2017 Development and validation of nomograms predictive of overall and progression-free survival in patients with oropharyngeal cancerJournal of Clinical Oncology.  35:4057-4065. 2017
    2017 Emotional Intelligence and Burnout in Academic Radiation Oncology ChairsJournal of Healthcare Management.  62:302-313. 2017
    2017 p16, HPV, and cetuximab: What is the evidence?Oncologist.  22:811-822. 2017
    2017 In replyJAMA Otolaryngology-Head and Neck Surgery.  143:526. 2017
    2017 Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522International Journal of Radiation Oncology - Biology - Physics.  97:687-699. 2017
    2016 Long-term results of a phase I/II trial of the addition of celecoxib to chemoradiotherapy for locally advanced or recurrent squamous cell carcinoma of the head-and-neckJournal of Radiation Oncology.  5:363-369. 2016
    2016 Analysis of Predictive Factors for Acute Esophagitis in Lung Cancer Radiation Therapy.International Journal of Radiation Oncology - Biology - Physics.  96:E193-E194. 2016
    2016 Analysis of Predictive Factors for Pneumonitis in Lung Cancer Radiation Therapy.International Journal of Radiation Oncology - Biology - Physics.  96:E482-E483. 2016
    2016 Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trialEuropean journal of cancer.  64:1-11. 2016
    2016 Cetuximab and radiotherapy in laryngeal preservation for cancers of the larynx and hypopharynx a secondary analysis of a randomized clinical trialJAMA Otolaryngology-Head and Neck Surgery.  142:842-849. 2016
    2016 Management of Advanced Head and Neck CancerNew England Journal of Medicine.  375:492. 2016
    2016 To the editorNew England Journal of Medicine.  375:492. 2016
    2016 Correction: Kinomic profiling of electromagnetic navigational bronchoscopy specimens: A new approach for personalized medicine (PLoS ONE (2016) 9:12 (e116388) DOI: 10.1371/journal.pone.0116388)PLoS ONE.  11. 2016
    2016 Cetuximab or cisplatin as a radiosensitizer in locoregionally advanced head and neck cancer: Recent resultsTranslational cancer research.  5:234-237. 2016
    2016 Association of Human Papillomavirus and p16 Status with Outcomes in the IMCL-9815 Phase III Registration Trial for Patients with Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated with Radiotherapy with or Without CetuximabJournal of Clinical Oncology.  34:1300-1308. 2016
    2016 Difference in restricted mean survival time for cost-effectiveness analysis using individual patient data meta-analysis: Evidence from a case studyPLoS ONE.  11. 2016
    2015 Enhancement of Cetuximab-Induced Radiosensitization by JAK-1 InhibitionBMC Cancer.  15. 2015
    2015 Society of chairs of academic radiation oncology programs-endorsed radiation oncology department review processInternational Journal of Radiation Oncology - Biology - Physics.  92:536-539. 2015
    2015 DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinomaOncotarget.  6:26995-27007. 2015
    2015 Targeting the effector domain of the myristoylated alanine rich C-kinase substrate enhances lung cancer radiation sensitivityInternational Journal of Oncology.  46:1079-1088. 2015
    2014 Kinomic profiling of electromagnetic navigational bronchoscopy specimens: A new approach for personalized medicinePLoS ONE.  9. 2014
    2014 Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522Journal of Clinical Oncology.  32:2940-2950. 2014
    2014 Pazopanib combined with radiation: In vivo model of interactionCancer Biotherapy and Radiopharmaceuticals.  29:247-250. 2014
    2014 Patterns of practice in radiation therapy for non-small cell lung cancer among members of the American Society for Radiation OncologyPractical Radiation Oncology.  4. 2014
    2014 African Americans with oropharyngeal carcinoma have significantly poorer outcomes despite similar rates of human papillomavirus-mediated carcinogenesisHuman Pathology.  45:310-319. 2014
    2014 Burnout in United States academic chairs of radiation oncology programsInternational Journal of Radiation Oncology - Biology - Physics.  88:363-368. 2014
    2014 Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolinesRadiotherapy and Oncology.  111:468-474. 2014
    2013 Stereotactic body radiation therapy (SBRT) for lung malignancies: Preliminary toxicity results using a flattening filter-free linear accelerator operating at 2400 monitor units per minuteRadiation Oncology.  8. 2013
    2013 Patterns of prophylactic gastrostomy tube placement in head and neck cancer patients: A consideration of the significance of social support and practice variationLaryngoscope.  123:1918-1925. 2013
    2013 Locoregional failure and the risk of distant metastasis after modern radiotherapy for head and neck cancerHead & neck surgery.  35:381-387. 2013
    2013 Cost effectiveness of modified fractionation radiotherapy versus conventional radiotherapy for unresected non-small-cell lung cancer patientsJournal of Thoracic Oncology.  8:1295-1307. 2013
    2013 Flattening filter-free linac improves treatment delivery efficiency in stereotactic body radiation therapyJournal of Applied Clinical Medical Physics.  14:4126. 2013
    2013 Flattening filter-free linac improves treatment delivery efficiency in stereotactic body radiation therapyJournal of Applied Clinical Medical Physics.  14:64-71. 2013
    2012 Prognostic significance of thyroid or cricoid cartilage invasion in laryngeal or hypopharyngeal cancer treated with organ preserving strategiesRadiation Oncology.  7. 2012
    2012 HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repairCancer Research.  72:4796-4806. 2012
    2012 Feasibility of exercising adults with asthma: a randomized pilot studyAllergy, Asthma & Clinical Immunology.  8. 2012
    2012 Hyperfractionated or accelerated radiotherapy in lung cancer: An individual patient data meta-analysisJournal of Clinical Oncology.  30:2788-2797. 2012
    2012 Kinomic profiling approach identifies Trk as a novel radiation modulatorRadiotherapy and Oncology.  103:380-387. 2012
    2012 MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for gliomaClinical Cancer Research.  18:3030-3041. 2012
    2012 Gastrostomy tube placement and use in patients with head and neck cancerHead & neck surgery.  34:422-428. 2012
    2012 Small-cell lung cancer: Prognostic factors and changing treatment over 15 yearsClinical Lung Cancer.  13:115-122. 2012
    2011 Impact of average weekly dose of radiation during radiotherapy alone or chemoradiotherapy in head and neck cancerHead & neck surgery.  33:1551-1556. 2011
    2011 Examination of laryngoesophageal dysfunction-free survival as an endpoint in nonsurgical treatment of squamous cell carcinomas of the larynx and hypopharynxCancer.  117:4447-4451. 2011
    2011 Treatment of small cell lung cancer with TRA-8 in combination with cisplatin and radiationRadiotherapy and Oncology.  101:183-189. 2011
    2011 Cetuximab augments cytotoxicity with poly (ADP-Ribose) polymerase inhibition in head and neck cancerPLoS ONE.  6. 2011
    2011 Dosimetric impact of target definitions on normal structures in head and neck cancerHead and Neck Oncology.  3. 2011
    2011 Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinomaRadiotherapy and Oncology.  99:339-343. 2011
    2011 The poly(ADP-ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapyRadiotherapy and Oncology.  99:331-338. 2011
    2011 Prophylactic percutaneous endoscopic gastrostomy tube placement in treatment of head and neck cancer: A comprehensive review and call for evidence-based medicineJournal of Parenteral and Enteral Nutrition.  35:365-374. 2011
    2011 Diagnosis-to-treatment interval and control of locoregionally advanced head and neck cancerArchives of Otolaryngology Head and Neck Surgery.  137:282-285. 2011
    2011 Dosimetric analysis of imaging changes following pulmonary stereotactic body radiation therapyAustralasian Radiology.  55:90-96. 2011
    2011 Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: Primary analysis of Radiation Therapy Oncology Group study RTOG 0214Journal of Clinical Oncology.  29:272-278. 2011
    2011 Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: Neurocognitive and quality-of-life analysisJournal of Clinical Oncology.  29:279-286. 2011
    2011 Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumors.Frontiers in Molecular Neuroscience.  4:47. 2011
    2011 Wound healing following combined radiation and cetuximab therapy in head and neck cancer patientsJournal of Wound Care.  20:166-170. 2011
    2010 Comparison of Methods to Reduce Dose to Swallowing-Related Structures in Head and Neck CancerInternational Journal of Radiation Oncology - Biology - Physics.  77:462-467. 2010
    2010 RapidArc Radiation Therapy: First Year Experience at the University of Alabama at BirminghamInternational Journal of Radiation Oncology - Biology - Physics.  77:932-941. 2010
    2010 Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapyJournal of Medicinal Chemistry.  53:586-594. 2010
    2010 Dosimetric Factors Associated With Long-Term Dysphagia After Definitive Radiotherapy for Squamous Cell Carcinoma of the Head and NeckInternational Journal of Radiation Oncology - Biology - Physics.  76:403-409. 2010
    2010 Margin on Gross Tumor Volume and Risk of Local Recurrence in Head-and-Neck CancerInternational Journal of Radiation Oncology - Biology - Physics.  76:164-168. 2010
    2010 Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survivalLancet Oncology.  11:21-28. 2010
    2009 Inhibition of STAT-3 results in radiosensitization of human squamous cell carcinomaRadiotherapy and Oncology.  92:339-344. 2009
    2009 Adjuvant radiotherapy for pancreatic cancer is associated with a survival benefit primarily in stage IIB patientsJournal of Gastroenterology.  44:84-91. 2009
    2009 Factors Associated With Long-Term Dysphagia After Definitive Radiotherapy for Locally Advanced Head-and-Neck CancerInternational Journal of Radiation Oncology - Biology - Physics.  73:410-415. 2009
    2009 EGFR FISH as a predictive factor for selection of patients with non-small cell lung cancer treated with cetuximab and chemotherapyAmerican Journal of Oncology Review.  8. 2009
    2008 Locoregionally Advanced Head and Neck Cancer Treated With Primary Radiotherapy: A Comparison of the Addition of Cetuximab or Chemotherapy and the Impact of Protocol TreatmentInternational Journal of Radiation Oncology - Biology - Physics.  71:676-681. 2008
    2008 Stage-specific survival differences associated with postoperative radiotherapy for gastrointestinal cancersJournal of Gastrointestinal Cancer.  39:86-99. 2008
    2007 Is cetuximab active in patients with cisplatin-refractory squamous cell carcinoma of the head and neck?: CommentaryNature Clinical Practice Oncology.  4:690-691. 2007
    2007 Design and development of water-soluble curcumin conjugates as potential anticancer agentsJournal of Medicinal Chemistry.  50:6284-6288. 2007
    2007 The authors reply [8]New England Journal of Medicine.  357:2202-2203. 2007
    2007 More on severe cutaneous reaction with radiotherapy and cetuximab [13]New England Journal of Medicine.  357:1872-1873. 2007
    2007 Biology of interactions: Antiepidermal growth factor receptor agentsJournal of Clinical Oncology.  25:4057-4065. 2007
    2007 Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53)Journal of Clinical Oncology.  25:3124-3129. 2007
    2007 Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximabJournal of Clinical Oncology.  25:2191-2197. 2007
    2007 A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: Cancer and Leukemia Group B 9734Clinical Lung Cancer.  8:268-272. 2007
    2007 Clinical cancer advances 2006: Major research advances in cancer treatment, prevention, and screening - A report from the American Society of Clinical OncologyJournal of Clinical Oncology.  25:146-162. 2007
    2006 Postoperative radiotherapy in non-small-cell lung cancer warrants further exploration in the era of adjuvant chemotherapy and conformal radiotherapyJournal of Clinical Oncology.  24:2978-2980. 2006
    2006 The authors and a colleague reply [11]New England Journal of Medicine.  354:2187. 2006
    2006 Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neckNew England Journal of Medicine.  354:567-578. 2006
    2006 Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): A meta-analysis of individual data from 1764 patientsAnnals of Oncology.  17:473-483. 2006
    2006 Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: A phase I studyAnti-Cancer Drugs.  17:95-102. 2006
    2005 Patterns of surgical care of lung cancer patientsAnnals of Thoracic Surgery.  80:2051-2056. 2005
    2005 Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderlyCancer.  103:2349-2354. 2005
    2005 Limited-stage small-cell lung cancer (stages I-III): Observations from the National Cancer Data BaseClinical Lung Cancer.  6:355-360. 2005
    2005 SU‐FF‐J‐123: Residual Tumor Motion in Respiratory Gated CT Treatment PlaningMedical Physics.  32:1948. 2005
    2004 Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structureBioconjugate Chemistry.  15:1264-1274. 2004
    2004 Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancerInternational Journal of Radiation Oncology - Biology - Physics.  59:943-951. 2004
    2004 Radiosensitization by Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in in Vitro and in Vivo Human Cancer ModelsClinical Cancer Research.  10:1263-1273. 2004
    2004 Adenoviral vector-mediated augmentation of epidermal growth factor receptor (EGFr) enhances the radiosensitization properties of anti-EGFr treatment in prostate cancer cellsInternational Journal of Radiation Oncology - Biology - Physics.  58:950-958. 2004
    2004 Anti-EGFR-mediated radiosensitization as a result of augmented EGFR expressionInternational Journal of Radiation Oncology - Biology - Physics.  59:S2-S10. 2004
    2004 Quality of life in 650 lung cancer survivors 6 months to 4 years after diagnosisMayo Clinic Proceedings.  79:1024-1030. 2004
    2003 The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderlyJournal of Clinical Oncology.  21:3201-3206. 2003
    2003 Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibodyJournal of Surgical Research.  111:274-283. 2003
    2003 Intraoperative radiotherapy for head and neck and skull base cancerHead & neck surgery.  25:217-225. 2003
    2003 Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug deliveryBioconjugate Chemistry.  14:302-310. 2003
    2003 Validation of target volume and position in respiratory gated CT planning and treatmentMedical Physics.  30:3196-3205. 2003
    2002 Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiationInternational Journal of Radiation Oncology - Biology - Physics.  54:1180-1193. 2002
    2002 Smoking behavior of 226 patients with diagnosis of stage IIIA/IIIB non-small cell lung cancerPSYCHO-ONCOLOGY.  11:472-478. 2002
    2002 Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancerInternational Journal of Radiation Oncology - Biology - Physics.  54:370-378. 2002
    2002 Epidermal growth factor receptor as a therapeutic target in head and neck cancer.Seminars in Radiation Oncology.  12:11-20. 2002
    2002 A new graphic for quality adjusted life years (Q-TWiST) survival analysis: The Q-TWiST plotQuality of Life Research.  11:37-45. 2002
    2002 Adjuvant radiation therapy after complete resection of non-small-cell lung cancer [3] (multiple letters)Journal of Clinical Oncology.  20:1427-1429. 2002
    2002 Model prediction of treatment planning for dose-fractionated radioimmunotherapy.Cancer.  94:1264-1269. 2002
    2002 A quality-adjusted reanalysis of a Phase III trial comparing once-daily thoracic radiation vs. twice-daily thoracic radiation in patients with limited-stage small-cell lung cancerInternational Journal of Radiation Oncology - Biology - Physics.  52:371-381. 2002
    2002 Effect of multileaf collimator leaf width on physical dose distributions in the treatment of CNS and head and neck neoplasms with intensity modulated radiation therapyMedical Physics.  29:1116-1119. 2002
    2002 Epidermal growth factor receptor as a therapeutic target in head and neck cancerSeminars in Radiation Oncology.  12:11-20. 2002
    2002 The possible use of uniform PORT doses is important in the SEER analysis, but undetected selection bias remains an issueClinical Lung Cancer.  4:45-46. 2002
    2001 Long-term results of a phase I/II study of high-dose thoracic radiotherapy with concomitant cisplatin and etoposide in limited stage small-cell lung cancerAmerican Journal of Clinical Oncology.  24:556-561. 2001
    2001 Balancing the possible effectiveness of postoperative radiotherapy for non-small-cell lung cancer against the possible detriment of radiation-induced toxicityJournal of Clinical Oncology.  19:3905-3907. 2001
    2001 Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancerJournal of Clinical Oncology.  19:3234-3243. 2001
    2000 Commentary "effectiveness of therapy on non-small-cell lung cancer"Clinical Lung Cancer.  2:191-192. 2000
    2000 Sensitivity and action of etoposide on malignant glioma cell linesCancer Radiothérapie.  4:57-64. 2000
    2000 Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers.Journal of Clinical Oncology.  18:47S-53S. 2000
    2000 A prospective evaluation of the timing of postoperative radiotherapy for preventing heterotopic ossification following traumatic acetabular fracturesInternational Journal of Radiation Oncology - Biology - Physics.  47:1347-1352. 2000
    2000 A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancerInternational Journal of Radiation Oncology - Biology - Physics.  47:939-944. 2000
    2000 Significance of neuron-specific enolase levels before and during therapy for small cell lung cancerClinical Cancer Research.  6:597-601. 2000
    2000 Non-small cell lung cancer: IntroductionSeminars in Radiation Oncology.  10:263-266. 2000
    2000 Point: The potential importance of elective nodal irradiation in the treatment of non-small cell lung cancerSeminars in Radiation Oncology.  10:308-314. 2000
    2000 Postoperative irradiation in non-small cell lung cancerSeminars in Radiation Oncology.  10:280-288. 2000
    2000 Unresectable or medically inoperable non-small cell lung cancer: The use of established clinical prognostic factors in making radiation-related treatment decisionsSeminars in Radiation Oncology.  10:267-273. 2000
    1999 Paclitaxel derivatives for targeted therapy of cancer: Toward the development of smart taxanesJournal of Medicinal Chemistry.  42:4919-4924. 1999
    1999 Factors predicting patterns of recurrence after resection of N1 non- small cell lung carcinomaAnnals of Thoracic Surgery.  68:1171-1176. 1999
    1999 Frequency of noncontiguous lymph node involvement in patients with resectable nonsmall cell lung carcinomaCancer.  86:1159-1164. 1999
    1999 Frequency of noncontiguous lymph node involvement in patients with resectable nonsmall cell lung carcinoma.Cancer.  86:1159-1164. 1999
    1999 Patients with stage I non-small cell lung carcinoma at postoperative risk for local recurrence, distant metastasis, and death: Implications related to the design of clinical trialsInternational Journal of Radiation Oncology - Biology - Physics.  45:315-321. 1999
    1999 Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinomaJournal of Clinical Oncology.  17:2681-2691. 1999
    1999 Patterns of failure and overall survival in patients with completely resected T3 N0 M0 non-small cell lung cancerInternational Journal of Radiation Oncology - Biology - Physics.  45:91-95. 1999
    1999 The role of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma: Seeking to optimize local control and survival while minimizing toxicityCancer.  86:195-196. 1999
    1999 The role of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma: seeking to optimize local control and survival while minimizing toxicity.Cancer.  86:195-196. 1999
    1999 Predictors of subclinical nodal involvement in clinical stages I and II non-small cell lung cancer: Implications in the inoperable and three- dimensional dose-escalation settingsInternational Journal of Radiation Oncology - Biology - Physics.  43:965-970. 1999
    1999 Combined modality therapy of A431 human epidermoid cancer using anti- EGFR antibody C225 and radiationCancer Biotherapy and Radiopharmaceuticals.  14:451-463. 1999
    1999 Current guidelines for the management of small cell lung cancerMayo Clinic Proceedings.  74:809-816. 1999
    1999 Sensitivity and action of etoposide on malignant glioma cell linesCancer Radiothérapie.  3:57-64. 1999
    1998 Ionizing radiation-induced MEK and Erk activation does not enhance survival of irradiated human squamous carcinoma cellsInternational Journal of Radiation Oncology - Biology - Physics.  42:921-925. 1998
    1998 Impact of beam energy and field margin on penumbra at lung tumor-lung parenchyma interfacesInternational Journal of Radiation Oncology - Biology - Physics.  41:707-713. 1998
    1998 Adjuvant radiotherapy for squamous cell carcinoma of the tongue base: Improved local-regional disease control compared with surgery aloneInternational Journal of Radiation Oncology - Biology - Physics.  41:371-377. 1998
    1998 The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinomaCancer.  82:1037-1048. 1998
    1998 The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: results of a North Central Cancer Treatment Group Phase III Study.Cancer.  82:1037-1048. 1998
    1998 Combined neck dissection and postoperative radiation therapy in the management of the high-risk neck: A matched-pair analysisInternational Journal of Radiation Oncology - Biology - Physics.  40:529-534. 1998
    1998 Spinal cord localization in the treatment of lung cancer: Use of radiographic landmarksInternational Journal of Radiation Oncology - Biology - Physics.  40:347-351. 1998
    1998 Bronchial carcinoid tumors: Importance of prognostic factors that influence patterns of recurrence and overall survivalRadiology.  208:181-185. 1998
    1998 Etoposide sensitivity of radioresistant human glioma cell linesCancer Chemotherapy and Pharmacology.  41:93-97. 1998
    1997 Has radiotherapy become too expensive to be considered a treatment option for early glottic cancer?Head & neck surgery.  19:692-700. 1997
    1997 Has radiotherapy become too expensive to be considered a treatment option for early glottic cancer?Head & neck surgery.  19:692-700. 1997
    1997 The impact of surgical adjuvant thoracic radiation therapy for patients with nonsmall cell lung carcinoma with ipsilateral mediastinal lymph node involvementCancer.  80:1399-1408. 1997
    1997 The impact of surgical adjuvant thoracic radiation therapy for patients with nonsmall cell lung carcinoma with ipsilateral mediastinal lymph node involvement.Cancer.  80:1399-1408. 1997
    1997 Utility of screening procedures for detecting recurrence of disease after complete response in patients with small cell lung carcinomaCancer.  80:676-680. 1997
    1997 Utility of screening procedures for detecting recurrence of disease after complete response in patients with small cell lung carcinoma.Cancer.  80:676-680. 1997
    1997 Laryngeal chondrosarcomas: The Mayo Clinic experienceJournal of Surgical Oncology.  65:269-273. 1997
    1997 Laryngeal chondrosarcomas: the Mayo Clinic experience.Journal of Surgical Oncology.  65:269-273. 1997
    1997 Postoperative localization of porta hepatis and abdominal vasculature in pancreatic malignancies: Implications for postoperative radiotherapy planningInternational Journal of Radiation Oncology - Biology - Physics.  39:51-56. 1997
    1997 Effectiveness of postoperative irradiation in stage IIIA non-small cell lung cancer according to regression tree analyses of recurrence risksAnnals of Thoracic Surgery.  64:1402-1407. 1997
    1996 The significance of the sequence of administration of topotecan and etoposideCancer Chemotherapy and Pharmacology.  39:109-112. 1996
    1996 The interaction of buthionine sulphoximide (BSO) and the topoisomerase I inhibitor CPT-11.The British journal of cancer. Supplement.  27. 1996
    1996 Radiation therapy for glottic cancer using 6-MV photons [5]Cancer.  78:183-184. 1996
    1996 Radiation therapy for glottic cancer using 6-MV photonsCancer.  77:381-386. 1996
    1996 Radiation therapy for glottic cancer using 6-MV photons.Cancer.  77:381-386. 1996
    1996 The interaction of buthionine sulphoximide (BSO) and the topoisomerase I inhibitor CPT-11British Journal of Cancer.  74. 1996
    1995 Long term results of a phase I/II study of aggressive chemotherapy and sequential upper and lower hemibody radiation for patients with extensive stage small cell lung cancer.Cancer.  76:406-412. 1995
    1995 Assessing the Interaction of Irradiation With Etoposide or IdarubicinMayo Clinic Proceedings.  70:1053-1060. 1995
    1995 Long term results of a phase I/II study of aggressive chemotherapy and sequential upper and lower hemibody radiation for patients with extensive stage small cell lung cancerCancer.  76:406-412. 1995
    1995 Management of stage ie primary gastric lymphomaActa Haematologica.  94:59-68. 1995
    1995 Prophylactic cranial irradiation in limited‐stage small cell lung cancerCancer.  75:1302-1309. 1995
    1994 Apoptosis occurs in lymphoma cells but not in hepatoma cells following ionizing radiation and photodynamic therapyDigestive Diseases and Sciences.  39:2467-2475. 1994
    1994 The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivitiesInternational Journal of Radiation Oncology - Biology - Physics.  29:243-247. 1994
    1994 Topoisomerase II-independent doxorubicin-induced cytotoxicity in an extremely doxorubicin-resistant cell lineBiochemical and Biophysical Research Communications.  198:582-589. 1994
    1994 Treatment of stage ie primary lymphoma of boneInternational Journal of Radiation Oncology - Biology - Physics.  28:363-372. 1994
    1994 Etoposide-resistance in the multidrug-resistant LZ-8 cellsBiochemistry and Molecular Biology International.  34:773-780. 1994
    1994 Limited-stage small-cell lung cancer: Patterns of intrathoracic recurrence and the implications for thoracic radiotherapyJournal of Clinical Oncology.  12:496-502. 1994
    1994 Postoperative adjuvant therapy for non-small cell lung cancer: a consensus reportLung Cancer.  11. 1994
    1994 Pretreatment minimal staging for non-small cell lung cancer: an updated consensus reportLung Cancer.  11. 1994
    1993 Malignant tracheoesophageal fistula in patients with esophageal cancerCancer.  72:1513-1521. 1993
    1993 Role of Radiation Therapy in the Management of Lung CancerMayo Clinic Proceedings.  68:593-602. 1993
    1993 The interaction of etoposide with radiation: Variation in cytotoxicity with the sequence of treatmentLife Sciences.  53. 1993
    1992 Interaction of buthionine sulfoximine and the stabilization of DNA-topoisomerase II complexes by doxorubicinInternational Journal of Radiation Oncology - Biology - Physics.  22:519-523. 1992
    1990 Doxorubicin decreases the repair of radiation-induced DNA damageInternational Journal of Radiation Biology.  57:55-64. 1990
    1989 Protection of doxorubicin cytotoxicity by cycloheximideInternational Journal of Radiation Oncology - Biology - Physics.  16:1209-1212. 1989
    1988 The management of vaginal melanomaCancer.  62:2066-2072. 1988

    Chapter

    Year Title Altmetric
    2011 Interaction of Chemotherapy and Radiation.  65-82. 2011
    2011 Nasopharyngeal Carcinoma.  619-638. 2011
    2006 Molecular Targets for Radiosensitization.  391-414. 2006

    Research Overview

  • Major Research Interests:
    1. The interaction of radiation and novel chemotherapeutic and biological agents.
    2. Gene therapy delivery of anti-EGFr single chain antibodies.
  • Principal Investigator On

  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2013 - 2015
  • Private Grant  awarded by DAIICHI SANKYO, INC. 2011 - 2012
  • Teaching Overview

  • TEACHING EXPERIENCE

    1. Radiation Oncology Residency Program (Participant in formal clinical and radiobiology lectures as well as daily “bedside” discussions concerning patient management), Mayo Clinic and UAB.

    2. Mayo Radiation Oncology Technology Program Radiobiology Lectures, 1990 – 1997.

    3. Director of Mayo Radiation Oncology Monthly Clinical Journal Club, 1991 – 1998.

    4. Awards received by residents who performed laboratory rotations: K. Minehan (recipient of ASTRO residents essay award for laboratory project), E. Durr (recipient of Radiation Research Society Travel Award), T. Sawyer (recipient of Morton Fellowship for laboratory project), R. Miller (recipient of ASTRO resident essay award for laboratory project, recipient of Morton Fellowship for laboratory project, recipient of American Radium Society residents essay award)

    5. Course director for Mayo Graduate School Course 5150su: Introductory Radiation Biology (Biophysics Sciences: 2 semester credits), 1995 – 1998 – designed entire semester course and taught a large portion of the course.

    6. Lecturer in the Tumor Biology Graduate School Program, Mayo Clinic, Rochester, MN, 1995 – 1998.

    7. Primary Director of First, Second and Third Annual Radiation Oncology Symposia in Scottsdale, Arizona - February 1997, February 1998, February 1999, respectively (collaboration with the Mayo Clinic): worked with CME office to set objectives, select faculty, organize teleconferences with faculty and moderated the Program. Also, obtained pharmaceutical company support for the project.

    8. Co-Director of the Fourth Annual Radiation Oncology Symposium in Orlando, Florida – July 2000 (collaboration with The University of Michigan): similar duties as first – third symposiums which were done in collaboration with the Mayo Clinic.

    9. Residency Director for the Department of Radiation Oncology at UAB, April 1998 – April 2001. The program was somewhat in disarray due to lack of faculty and no Department Chairman for three years. Worked to recruit excellent residents and build the educational component of the program. We started a core curriculum of 52 lectures per year. This core curriculum was intended to cover all major cancer treatments. This program exists today.

    10. Co-Director of Translational Research meeting sponsored by the American Society of Therapeutic Radiology (ASTRO): San Francisco, CA – August 5 – 6, 2005.

    11. Numerous co-director positions for CME courses (see invited presentations): 2005 – Present, (most recently co-director of International HPV in Cancer Conference, Amsterdam, November 2010. Sponsored by Lancet Oncology).
  • Full Name

  • James Bonner